Urodynamix Technologies Ltd.

Urodynamix Technologies Ltd.

May 20, 2008 09:00 ET

Urodynamix and Laborie Launch Tetra™ Bladder Monitor System

A Revolution in Bladder Diagnostics

VANCOUVER, BRITISH COLUMBIA--(Marketwire - May 20, 2008) - Urodynamix Technologies Ltd. (TSX VENTURE:URO) and Laborie Medical Technologies today announced the U.S. launch of the Tetra™ Bladder Monitor System, a catheter-free medical device that uses near infrared spectroscopy (NIRS) to aid in the diagnosis of lower urinary tract symptoms (LUTS).

The announcement was made as Laborie began introducing Tetra to its large installed base of key opinion leaders and academic urologists at the 103rd American Urological Association (AUA) Annual Meeting and Exhibition, the largest urology conference in the world, in Orlando, Florida.

Tetra is used in conjunction with other non-invasive tests (including uroflowmetry and bladder ultrasound) to assess bladder function and aid in the diagnosis of LUTS. These symptoms are particularly common in men with benign prostatic hyperplasia, or BPH (enlarged prostate), and Tetra provides clinicians with an alternative to more invasive, catheter-based procedures that are currently used to diagnose prostate obstruction and related conditions.

"A urologist now has more options to diagnose and treat the patient, and when combined with our excellent urodynamic systems, Tetra presents a high performance option that fits nicely into our growing portfolio of products," said Ing Goping, Chief Scientific Officer of Laborie. "Tetra NIRS is a prime example of our commitment as a technology provider to facilitate the access of new applications and possibilities in this exciting field."

In May 2007, Urodynamix entered into a worldwide licensing agreement with Laborie, the global market leader in urodynamics equipment and related products, to distribute its URO-NIRS device in acute care settings (see news release dated May 17, 2007 for details). Laborie is the worldwide leader in urodynamics equipment used for the diagnosis and treatment of incontinence, with a global network consisting of direct sales representatives and distributors in 52 countries across North America, South America, Europe, Asia and Oceania.

Lower urinary tract symptoms are common in middle-aged men, with the prevalence of LUTS believed to be as high as 90% in men aged 50 to 80 years old. The term describes a range of urinary symptoms that may be linked with prostate disease or bladder dysfunction. LUTS are most often associated with an enlarged prostate; however symptoms alone cannot be used to make an accurate diagnosis or ensure appropriate treatment of the underlying disease. In the past, invasive pressure-flow urodynamic studies were the only way to differentiate between symptoms caused by prostatic obstruction and bladder disease.

About Tetra™

Laborie's Tetra™ Bladder Monitor System uses a non-invasive optical sensing technique (near infrared spectroscopy, or NIRS) to aid in the diagnosis of patients with lower urinary tract symptoms without the use of catheters. FDA pivotal trials of Tetra demonstrated 86% sensitivity and 89% specificity for the presence or absence of prostate obstruction compared to a gold-standard diagnosis based on the Abrams-Griffiths nomogram.

Tetra provides a fast, catheter-free procedure for suitable patients, and adds no further risk to the patient with regard to infections and other post-procedure side-effects. The test is easy to administer within conventional urodynamic settings, and can be operated without extra clinical resources.

Tetra is intended for use under the direction of a licensed physical or health care professional in an office or hospital setting.

About AUA 2008

The American Urological Association's Annual Meeting is the world's largest meeting of urologic professionals. More than 10,000 urologists and health care professionals and 5,000 exhibitors will be in attendance with over 350 exhibitors showcasing their urological products or services.

About Urodynamix Technologies Ltd.

Urodynamix Technologies is a Canadian medical device company developing and commercializing non-invasive medical technology based on proprietary applications of near-infrared spectroscopy (NIRS). The Company is currently focused on products that aid in the diagnosis and treatment of urinary incontinence, lower urinary tract symptoms, prostate cancer, benign prostatic hyperplasia, and traumatic increases in intra-abdominal pressure that cause abdominal compartment syndrome. Urodynamix's breakthrough medical technology has the potential to beneficially affect more than 200 million people worldwide.

Certain information contained in this press release may be forward-looking and is subject to unknown risks, which could cause actual results to differ materially from those set forth or implied herein. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove correct.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Contact Information